Vertebral Augmentation With Kyphoplasty vs Nonsurgical Mgmt for Vertebral Body Compression Fractures

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01175278
Recruitment Status : Withdrawn (No enrollment)
First Posted : August 4, 2010
Last Update Posted : January 12, 2012
Medtronics, Inc.
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute

Brief Summary:
The purpose of this study is to find out how balloon kyphoplasty (surgical repair of the patient's fracture using balloons and bone cement) compares to non-surgical treatment in reducing vertebral compression fractures while providing pain relief and improved function and quality of life.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Procedure: Vertebral Augmentation with Balloon Kyphoplasty Other: Non-surgical Treatment Not Applicable

Detailed Description:

This is a prospective single center study designed to compare balloon kyphoplasty to non-surgical management (NSM) in the treatment of mildly painful, acute vertebral body compression fractures in multiple myeloma patients. Because of the pilot nature and the small sample size of the study, patient randomization will NOT be stratified. Patients with mildly symptomatic vertebral compression fractures (VCFs) will undergo a 1:1 randomization either balloon kyphoplasty or non surgical management. Randomization assignments will be generated by computer and investigator notified once the patient enrolled.

The observational arm will be compared to each of the other two arms; control and intervention arm using the same outcome variables and statistical methods.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Vertebral Augmentation With Kyphoplasty Versus Nonsurgical Management in Multiple Myeloma Patients With Mildly Symptomatic Vertebral Body Compression Fractures
Study Start Date : July 2010
Actual Primary Completion Date : May 2011
Actual Study Completion Date : May 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
No Intervention: Observation Arm
Patients who are asymptomatic (no symptoms) will participate in the observational portion of the study.
Experimental: Balloon Kypholasty Procedure: Vertebral Augmentation with Balloon Kyphoplasty
Two small metal tubes will be inserted through the skin into the collapsed bone. Inflatable bone tamps (balloon catheters) will be inserted through each of these two tubes into the bone. The balloons will be inflated with a liquid that can be seen on xrays (contrast) to return the bone toward its natural shape and create a cavity. The balloons will then be deflated and removed. The cavity in the bone will be filled with bone cement to stabilize the broken backbone.

Active Comparator: Control Arm
Non-surgical Management Treatment Group
Other: Non-surgical Treatment
Non-surgical treatment means the institution of therapies other than cancer chemotherapy and surgical treatment aimed at alleviation of back pain and restoration of decreased function associated with the patient's VCF(s).

Primary Outcome Measures :
  1. Time to Vertebral Event [ Time Frame: Average of 12 months ]
    Time to vertebral event (composite end point of pain progression, hospitalization for pain, and rescue vertebral augmentation or surgery or radiation therapy as related to an index fracture)

  2. Time to Pain Progression [ Time Frame: Average of 12 months ]
    Time to pain progression defined as the time to the development of pain severity rated greater than 4 on the visual analog scale (VAS) as related to an index fracture

Secondary Outcome Measures :
  1. Rate of Vertebral Events [ Time Frame: 12 months ]
    Rate of vertebral events in patients with asymptomatic vertebral compression fracture at 12 months

  2. Rate of Hospitalization [ Time Frame: 12 months ]
    Rate of hospitalization for pain control in patients with asymptomatic or mildly symptomatic vertebral compression fracture at 12 months

  3. Complications of Procedure [ Time Frame: Average of 12 months ]
    Complications of vertebral augmentation

  4. Quality of Life Questionnaire Results [ Time Frame: Average of 12 months ]
    Quality of life as assessed by the Functional Assessment of Cancer Treatment - General (FACT-G) questionnaire in all enrolled patients and Roland Morris disability questionnaire for spine disability

  5. Changes in Pulmonary Function [ Time Frame: Average of 12 months ]
    Changes in pulmonary function testing in patients with thoracic spine vertebral compression fracture

  6. Change in Kyphosis [ Time Frame: Average of 12 months ]
    Change in kyphosis as measured by the Cobb method and change in vertebral collapse by the method of Genant

  7. Prognostic Ability of Bone Biomarkers [ Time Frame: Average of 12 months ]
    Prognostic ability of bone biomarkers for the prediction of vertebral events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with multiple myeloma (active or smoldering) with mild back pain (Visual Analog Scale [VAS]) ≤ 4 or no back pain (VAS=0) on a stable analgesic regimen) related to vertebral compression fractures (at least one and up to 8 index fractures from T3 to L5) as seen on magnetic resonancy imaging (MRI), computed axial tomography (CT) scan or plain radiographs.
  • No major planned spine surgery for at least 6 months following enrollment.
  • No evidence of epidural disease or cord compromise on magnetic resonance imaging.
  • Life expectancy greater than 6 months.
  • Adequate myeloma systemic control (no evidence of active progressive disease). No planned change in chemotherapy regimen for 1 month prior and for at least 1 month following enrollment. Change in dose(s) permitted.
  • Adequate hematologic parameters (platelet count≥50,000/μL, and absolute neutrophil count ≥1,000). Platelet transfusions are permitted to increase platelet counts perioperatively.
  • Age greater than 21 years and able to understand and sign the informed consent document.

Exclusion Criteria:

  • Patients with significant comorbidities (aside from the index fracture or cancer) which would result in an unacceptable surgical risk or patients with contraindications to general or local anesthesia.
  • Patients with other primary tumors including primary bone tumors or solitary plasmacytoma at site of the index VCF.
  • VCF morphology deemed unsuitable for balloon kyphoplasty (vertebra planum).
  • Additional non-kyphoplasty surgical treatment is required for the index fracture.
  • Patients with uncontrolled pain related to the VCF (VAS>4, or increasing opioid requirements), or with epidural disease on magnetic resonance imaging. Spinal cord compression , canal compromise and /or spinal instability requiring decompression.
  • Patients with a bleeding disorder which cannot be adequately managed perioperatively.
  • Patients with pain unrelated to the VCF according to the investigators.
  • Patients with estimated survival less than 6 months.
  • Known allergy to bone cement or all contrast media used in the treatment of study participants.
  • MRI contraindication (e.g., cerebral aneurysm clips, pacemaker, implanted biostimulators, cochlear implants, penile prosthesis).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01175278

Sponsors and Collaborators
H. Lee Moffitt Cancer Center and Research Institute
Medtronics, Inc.
Principal Investigator: Frank Vrionis, M.D. H. Lee Moffitt Cancer Center and Research Institute

Additional Information:
Responsible Party: H. Lee Moffitt Cancer Center and Research Institute Identifier: NCT01175278     History of Changes
Other Study ID Numbers: MCC-15839
Pro00000214 ( Other Identifier: USF Institutional Review Board )
First Posted: August 4, 2010    Key Record Dates
Last Update Posted: January 12, 2012
Last Verified: January 2012

Keywords provided by H. Lee Moffitt Cancer Center and Research Institute:

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Fractures, Compression
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Fractures, Bone
Wounds and Injuries